Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) lost 0.3% and ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $167 from $143 and keeps a Buy rating on the shares ...

Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following ...

UBS analysts increased the price target on Axsome Therapeutics (NASDAQ:AXSM) shares to $133.00, up from the previous $105.00, while maintaining a Buy rating on the stock. The company, currently valued ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Highlights,Axsome Therapeutics stock reached a new 52-week high following an updated price target from financial ...